Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenal Gland Disorders01:27

Adrenal Gland Disorders

Adrenal gland disorders manifest when the production of adrenal hormones deviates from the norm, resulting in either excessive or insufficient concentrations.
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Investigating the Source and Impact of Elevated Intraocular Insulin Levels in High Myopia.

Current eye research·2026
Same author

Multiomics prediction and immunogenic validation of personalized neoantigens in cholangiocarcinoma patients.

Journal of translational medicine·2026
Same author

Mitigating Intraoperative Fatigue in Surgeons at High Altitude: A Stepped-Wedge Cluster Randomized Trial.

High altitude medicine & biology·2026
Same author

Minimizing Implant Rejections through Low-Inflammatory and Immune-Regulatory Biointerfaces.

ACS applied materials & interfaces·2026
Same author

Wandering spleen.

Hepatobiliary surgery and nutrition·2026
Same author

Rethinking nutritional risk in cancer: muscle quality, myosteatosis, and prognosis.

Hepatobiliary surgery and nutrition·2026

Related Experiment Video

Updated: Jun 5, 2026

A Novel Method: Super-selective Adrenal Venous Sampling
06:08

A Novel Method: Super-selective Adrenal Venous Sampling

Published on: September 15, 2017

Primary aldosteronism beyond laterality: integrating subtype assignment with outcome-oriented risk stratification.

Shida Chen1, Haifeng Xu2, Chengan Xu3

  • 1Department of Endocrinology, The Second People's Hospital of Bengbu City, Bengbu, China.

Frontiers in Endocrinology
|June 4, 2026
PubMed
Summary
This summary is machine-generated.

Primary aldosteronism (PA) diagnosis needs more than just anatomical laterality. A multidimensional approach considering hormonal activity and molecular factors is crucial for accurate risk stratification and treatment adequacy in PA.

Keywords:
adrenal venous samplingcardiovascular riskprimary aldosteronismrisk stratificationsteroidomics

Related Experiment Videos

Last Updated: Jun 5, 2026

A Novel Method: Super-selective Adrenal Venous Sampling
06:08

A Novel Method: Super-selective Adrenal Venous Sampling

Published on: September 15, 2017

Area of Science:

  • Endocrinology
  • Cardiovascular Medicine
  • Nephrology

Background:

  • Primary aldosteronism (PA) is traditionally classified by anatomical subtypes (unilateral vs. bilateral).
  • This classification, while essential for initial treatment, doesn't fully explain diverse patient outcomes.
  • Heterogeneity in cardiovascular, renal, and metabolic complications is observed despite anatomical classification.

Purpose of the Study:

  • To review the limitations of the traditional anatomical paradigm for PA risk stratification.
  • To summarize emerging evidence for a multidimensional framework for PA.
  • To discuss implications for treatment assessment and future research.

Main Methods:

  • Literature review examining current evidence on PA prognosis.
  • Analysis of factors beyond laterality influencing PA outcomes.
  • Discussion of a multidimensional risk stratification model.

Main Results:

  • Long-term PA prognosis depends on more than laterality, including mineralocorticoid receptor activation burden, hormonal activity, and tissue susceptibility.
  • Clinical factors like organ damage, renin suppression, aldosterone excess magnitude, and molecular features offer complementary prognostic information.
  • Laterality alone is insufficient for comprehensive longitudinal risk stratification and assessing treatment adequacy.

Conclusions:

  • A multidimensional framework integrating clinical burden, hormonal activity, and molecular context is needed for PA.
  • PA should be viewed as a stratifiable cardiometabolic condition, not just an anatomical subtype.
  • Estimating residual organ risk is as important as determining anatomical laterality for PA management.